ArticleJournal of cancer research and clinical oncology2010

The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer.

Ramazan Yildiz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.